We are international
Donate
TEXT SIZE   


Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD
IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy

12.17.14

Program: Oral and Poster Abstracts
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II
Giampaolo Merlini, MD1, Vaishali Sanchorawala, MD2, Zonder A Jeffrey, MD3*, Vishal Kukreti, MD, FRCPC4, Stefan O Schoenland, MD5*, Arnaud Jaccard, MD6*, Angela Dispenzieri, MD7, Adam D. Cohen, MD8, Deborah Berg, RN, MSN9, Zheng Yuan, PhD10*, Ai-Min Hui, MD, PhD11, Palladini Giovanni, MD, PhD12* and Raymond L. Comenzo, MD13

1Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Department of Molecular Medicine, Pavia, Italy
2Hematology/Oncology, Boston University School of Medicine, Boston, MA
3Karmanos Cancer Institute, Wayne State University, Detroit, MI
4Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
5University of Heidelberg, Heidelberg, Germany
6Clinical haematology, CHU Limoges, Limoges, France
7Division of Hematology, Mayo Clinic, Rochester, MN
8Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
9Millennium: The Takeda Oncology Company, Cambridge, MA
10Takeda Pharmaceuticals International, Co., Cambridge, MA
11Takeda Pharmaceuticals International Co., Cambridge, MA
12University of Pavia, Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Pavia, Italy
13Division of Hematology-Oncology, Tufts Medical Center, Boston, MA

 
Background

Systemic AL amyloidosis is a life-threatening disease with limited treatment options. Response criteria have been recently updated and retrospectively validated (Palladini et al, J Clin Oncol 2012). Hematologic response (suppression of FLCs) has been shown to predict for both organ response and survival (ibid). Preliminary results from the present phase 1 study (NCT01318902) regarding the safety, tolerability, and maximum tolerated dose (MTD) of ixazomib (the first oral PI to be investigated in the clinic) in RRAL were reported previously (Merlini et al, ASH 2012). At that time, 11 pts had received the MTD/RP3D of ixazomib - 4.0 mg. Here we update the safety data (primary objective) and report hematologic and organ responses, progression-free survival (PFS), and overall survival (OS) (secondary objectives) for the extended population of 22 pts receiving the RP3D.

 

Methods

Pts with RRAL after ≥1 prior therapy and with measureable heart/kidney involvement and cardiac biomarker stage I/II disease were eligible. Two expansion cohorts (PI-naïve and PI-exposed) were enrolled at the RP3D. Pts received oral ixazomib on days 1, 8, and 15 for up to 12 x 28-day cycles; continuation until disease progression was allowed. Pts with less than partial response (PR) after 3 cycles received added dexamethasone (Dex) 40 mg, days 1–4 from cycle 4 onwards. Adverse events (AEs) were graded by NCI-CTCAE v4.03. Responses were assessed per standard criteria (Palladini et al, J Clin Oncol 2012).

 

Results

At data cut-off (Dec 6, 2013), 27 pts had been enrolled, 22 at the RP3D of ixazomib 4.0 mg; the other 5 pts were enrolled at 5.5 mg and are not included in these analyses. In pts who received ixazomib 4.0 mg, median age was 64.5 yrs (range 54–78); 13 were male. Mayo cardiac biomarker risk stage was I/II/III in 11/10/1 pts, respectively. Median baseline FLC differential (dFLC) and NT-proBNP were 146 mg/L (range 40–734) and 849 pg/mL (range 51–5691). Major organ involvement included heart, kidney, or both in 9, 8, and 5 pts, with a median of 2 (range 1–6) organ systems involved. Pts had received a median of 3 prior therapies, including transplantation in 16 pts; 16 pts had received prior bortezomib (PI exposed) and 6 were PI naïve. Other prior therapies included melphalan (n=21), Dex (n=16), IMiDs (n=11), and cyclophosphamide (n=10). Best hematologic response to prior therapy was complete response (CR) in 3 pts, very good PR (VGPR) in 4, PR in 14, and stable disease (SD) in 1 pt; organ response was achieved by 5 pts, with 12 pts having no response. Exposure and outcome data by prior PI exposure are shown in the table. Pts discontinued due to disease progression (n=6), pt withdrawal, symptomatic deterioration (each n=3), or unsatisfactory response (n=2); 5 pts completed 12 cycles; 3 pts are ongoing. Overall hematologic response rate (ORR) was 52%. After a median follow-up of 16.9 mos, the 9 pts who achieved ≥VGPR, had a median PFS of 17.0 mos compared with 10.7 mos in pts who achieved a lesser response (p=0.03). Cardiac/renal response was observed in 50%/18% of pts (all ≥VGPR). The most common drug-related AEs included diarrhea, nausea (each n=7), fatigue, thrombocytopenia (each n=6), peripheral neuropathy, and pyrexia (each n=4). Drug-related grade 3 AEs (>1 pt) were thrombocytopenia (n=3), diarrhea, and maculo-papular rash (each n=2).

 

Conclusions

This is one of the first studies prospectively assessing hematologic and organ response according to the updated consensus criteria. These data suggest weekly oral ixazomib 4.0 mg is feasible and generally well tolerated in RRAL pts with vital organ dysfunction. High quality hematologic responses (≥VGPR) were observed in 43% of pts; these responses were sustained at 1 yr in 60% of this heavily-pretreated population. Achieving ≥VGPR was associated with cardiac response and extended PFS. These results warrant a phase 3 study of ixazomib plus Dex vs physician's choice of treatment, which is ongoing (NCT01659658).


 related articles
ASH 2014: Dr. Jeffre...
ASH 2014: Dr. Keith ...
ASH 2014: Dr. Ravi V...
ASH 2014: Dr. Shaji ...
Diffusion-Weighted M...
Evaluation of Curren...
Hevylite® to Monitor...
Hevylite® to Monitor...
In Multiple Myeloma,...
Landscape of Driver ...
PET-CT Has Major Dia...
The Presence of FDG ...
Utility of Serum Fre...
Whole-Body Reduced-D...
Connect MM®—the Mult...
Final Results from t...
Impact of Beta Block...
Meta-Analysis of Pha...
Oprozomib and Dexame...
Car-Bird [Carfilzomi...
Carfilzomib, Lenalid...
Carfilzomib, Lenalid...
Connect MM®—the Mult...
Long-Term Ixazomib M...
Long-Term Outcome of...
Phase I Study of the...
Pomalidomide, Bortez...
A Phase I Trial of P...
Carfilzomib, Lenalid...
Leopard: A Phase II ...
Myeloma Minute
...

Pomalidomide Plus Lo...
Pomalidomide, Cyclop...
Safety and Efficacy ...
SWOG 1211: Initial R...
The Combination of B...
Three Drug Combinati...
Adverse Cytogenetics...
Autologous Followed ...
Prospective Molecula...
A Phase I Study of H...
Pomalidomide, Cyclop...
A Phase Ib Dose Esca...
Safety and Efficacy ...
Safety and Efficacy ...
Serum Free Light Cha...
Utility of Serum Fre...
Critical Issues Need...
News Briefing: The L...
The IMWG Conference ...
ASH 2014 Social Medi...

ASH 2014: Dr. Jeffrey Zonder's Overview
ASH 2014: Dr. Keith Stewart's Overview
ASH 2014: Dr. Ravi Vij's Overview
ASH 2014: Dr. Shaji Kumar's Overview
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma
Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic
Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma
Hevylite® to Monitor Response to Therapy in Multiple Myeloma
In Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study
Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response
PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma
The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Whole-Body Reduced-Dose CT as Primary Staging and During Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients
Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma
Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma
A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments
Myeloma Minute
March 5, 2015
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)
The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma
Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment
Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy
Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma
Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Critical Issues Need Answers:
Providing Best Options for Myeloma Treatments in 2014
News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
The IMWG Conference Series "Making Sense of Treatment"
56th ASH Annual Meeting | Dec. 8, 2014
ASH 2014 Social Media Team


You might also be interested in:

Overviews
ASH 2014: Dr. Jeffrey Zonder's Overview

Jeffrey Zonder, MD
Karmanos Cancer Institute
Wayne State University
Detroit, MI, USA

 


ASH 2014: Dr. Keith Stewart's Overview
Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA

ASH 2014: Dr. Ravi Vij's Overview
Ravi Vij, MD
Washington University School of Medicine
St. Louis, MO, USA

ASH 2014: Dr. Shaji Kumar's Overview

Shaji Kumar, MD
Professor of Medicine, Division of Hematology
Mayo Clinic, Rochester, MN


Diagnostics, Genetics, Other Research
Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma

Evangelos Terpos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece


Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic

Roman Hajek, MD
University of Ostrava
Ostrava, Czech Republic


Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma

Xavier Leleu, MD
Hopital Claude Huriez
CHRU Lille
Lille, France


Hevylite® to Monitor Response to Therapy in Multiple Myeloma

Xavier Leleu, MD
Hopital Claude Huriez
CHRU Lille
Lille, France


In Multiple Myeloma, High-Risk Features Are Modulated By Other Chromosomal changes : A Large Snparray IFM Study

Jill Corre, MD
Unité de Génomique du Myélome
Toulouse, France


Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD
Institute for Molecular Medicine Finland (FIMM)
University of Helsinki
Helsinki, Finland


PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma

Brittany Dykstra, MD
Mayo Clinic
Rochester, MN, USA


The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD
Seràgnoli Institute of Hematology
Bologna University School of Medicine
Bologna, Italy


Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD
Mayo Clinic
Rochester, MN


Whole-Body Reduced-Dose CT as Primary Staging and During Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial

Katja Weisel, MD
University Hospital Tubingen
Tubingen, Germany


Other Novel Agents
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin Shah, MD
MD Anderson Cancer Center
Houston, TX, USA


Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Heinz Ludwig, MD
Wilhelminenspital
Vienna, Austria


Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients

Yi Lisa Hwa, DNP
Mayo Clinic
Rochester, MN, USA


Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma

Parameswaran N. Hari, MD
Medical College of Wisconsin
Milwaukee, WI


Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Parameswaran N. Hari, MD
Department of Medicine
Medical College of Wisconsin
Milwaukee, WI, USA


Proteosome Inhibitors
Car-Bird [Carfilzomib, Clarithromycin(Biaxin®), Lenalidomide/(Revlimid®), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer Mark, MD
Weill Cornell Medical College
New York, NY, USA


Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study

Ola Landgren, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY, USA


Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA


Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin Shah, MD
MD Anderson Cancer Center
Houston, TX, USA


Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD
Mayo Clinic,
Rochester, MN, USA


Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD
IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy


Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan Kaufman, MD
Winship Cancer Institute
Emory University
Atlanta, GA, USA


Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA


Immunomodulatory Agents
A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Jeffrey Zonder, MD
Karmanos Cancer Institute
Wayne State University
Detroit, MI, USA


Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ, USA


Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Andrew Spencer, MD
Alfred Hospital-Monash University
Melbourne, Australia


Myeloma Minute
March 5, 2015

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses

Martha Lacy, MD
Mayo Clinic
Rochester, MN, USA


Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA
 


Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD
Department of Clinical Therapeutics
University of Athens School of Medicine
Athens, Greece


SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Saad Usmani, MD
Levine Cancer Institute
Charlotte, NC, USA


The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece


Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios Dimopoulos, MD
Department of Clinical Therapeutics
National and Kapodistrian University of Athens School of Medicine
Athens, Greece


Transplantation
Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy

Gregory P. Kaufman, MD
Mayo Clinic
Rochester, MN, USA


Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma

Stefan Knop, MD
Wuerzburg University Medical Center
Wuerzburg, Germany


Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Benedetto Bruno, MD
University of Torino
Torino, Italy

 


Alkylating Agents
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Emma Scott, MD
Knight Cancer Institute
Oregon Health and Science University
Portland, OR, USA


Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA
 


Anti-CD38 Agents
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD
University of California San Francisco
San Francisco, CA, USA


Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD
Department of Clinical Therapeutics
University of Athens School of Medicine
Athens, Greece


Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
Torben Plesner, MD
Vejle Hospital
Vejle, Denmark

Serum Free Light Chains
Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Jill Corre, MD
Unité de Génomique du Myélome
Toulouse, France


Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response

Muhamad Alhaj Moustafa, MD
Mayo Clinic
Rochester, MN


Events
Critical Issues Need Answers:
Providing Best Options for Myeloma Treatments in 2014

Friday, Dec. 5, 2014
12:00pm PT
Moscone Center
San Francisco, California


News Briefing: The Latest on Blood Cancers – From Advances to Patient Advantages
Sunday, Dec. 7, 2014
8:00pm PT
San Francisco, California

The IMWG Conference Series "Making Sense of Treatment"
56th ASH Annual Meeting | Dec. 8, 2014
  • ASH Oral and Posters Overview and High Risk Smoldering MM
  • Frontline Therapy
  • Role of MRD
  • Transplant
  • Maintenance / Continous Therapy
  • Imaging
  • Relapse and New Drugs

Social Media Team
ASH 2014 Social Media Team
Tune in as the IMF brings myeloma support group leaders and patients to San Francisco for the 56th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 20,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#IMFASH2014), Facebook, blogs and videos.